您现在的位置是:首页 》 发表论文

浏览论文(根据年份):
All
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Before 2006
授权专利(12项目):
详细

2018  (2 / Total 113 )

  • 1
    Lai J, Lu D, Zhang C, Zhu H, Gao L, Wang Y, Bao R, Zhao Y, Jia B, Wang F, Yang Z, Liu Z. Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy. Biomaterials. 2018 Mar;158:1-9.
    Abstract:
    Increasing evidence indicates that the overexpression of galectin-1, a member of the galectin family, is related to tumor progression and invasion, as well as tumor resistance to therapies (e.g., radiotherapy). Herein, we investigated whether near-infrared fluorescence (NIRF) imaging and positron-emission tomography (PET) were sensitive approaches for detecting and quantitating galectin-1 upregulation in vivo. An anti-galectin-1 antibody was labeled with either an NIRF dye or 64Cu, and NIRF and PET imaging using the resulting probes (Dye-αGal-1 and 64Cu- 1,4,7-triazacyclononane-1,4,7-triacetic acid [NOTA]-αGal-1) were performed in 4T1 breast cancer-bearing mice treated with several rounds of sorafenib. Radiotherapy was performed in vitro and in vivo to identify the role of galectin-1 in radioresistance. NIRF and PET imaging both revealed significantly increased upregulation of galectin-1 in the hypoxic tumors after sorafenib treatment, which was verified by ex vivo biodistribution, western blotting, and enzyme-linked immunosorbent assays. Galectin-1 specific inhibition by thiodigalactoside dramatically improved the efficacy of radiotherapy, and overcame sorafenib-induced radiotherapy resistance. Taken together, galectin-1 is a key mediator of tumor resistance to radiotherapy. Targeted molecular imaging allows for real-time, noninvasive, and quantitative detection of the dynamic changes in galectin-1 levels in vivo; this introduces the possibility of early detection of tumor resistance to therapies.

    Keywords: (64)Cu; Galectin-1; Hypoxia; ImmunoPET; Radiotherapy.
  • 2
    Jia B, Zhang X, Wang B, Chen M, Lv F, Wang S, Wang F. Dual-Modal Probe Based on Polythiophene Derivative for Pre- and Intraoperative Mapping of Lymph Nodes by SPECT/Optical Imaging. ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6646-6651.
    Abstract:
    The metastatic spread of primary tumors to regional lymph nodes (LNs) is an important prognostic indicator for cancer staging and clinical therapy. Therefore, developing lymphatic mapping probes with improved accuracy and efficiency is of vital importance. Conjugated polymers (CPs) have been established as useful optical probes for sensitive biological and chemical detection. As a member of CPs family, polythiophene derivatives have drawn increasing attraction because of their superior photostability, signal amplification ability, and flexible structures for modification. In addition, these excellent properties allow the promising in vivo application to real-time LNs mapping. Here, we first reported a radiolabeled dual-modal probe based on the polythiophene derivative (99mTc-PTP) that was used for LNs mapping with high sensitivity and specificity by preoperative single-photon emission computed tomography imaging and intraoperative optical guidance. 99mTc-PTP exhibits an excellent radio-fluorescence guidance ability and a remarkable biocompatibility and holds great potential to be a powerful probe for noninvasive LNs mapping.

    Keywords: SPECT imaging; dual modality; lymph nodes mapping; optical imaging; polythiophene.

中心地址:北京市海淀区学院路38号  电话:010-82802871  传真:010-82801145    邮编:100191
北京大学医学同位素研究中心, 京ICP备15055835